N/A N=36 COVID-19 SARS-CoV-2 Screening Protocol
Covid19
Primary: Participants Enrolled — 36 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=130 COVID-19 First In Human Study to Evaluate Safety, Tolerability, and Pharmacokinetics of EIDD-2801 in Healthy Volunteers
Coronavirus
Primary: Part 1: Number of Participants With Treatment Emergent Adverse Events and Severity of Treatment Emergent Adverse Events — 7; 2; 0; 3 Participants
Phase 1 N=23 RU Anti-SARS-CoV-2 (COVID-19) mAbs in Healthy Volunteers
Covid19
Primary: Grade 2 and Higher Adverse Events 4 Weeks After Administration. — 0; 0; 0; 0 Participants
N/A N=36 SARS-CoV-2 Human Challenge Characterisation Study
Covid19 · SARS-CoV Infection · Corona Virus Infection
Primary: Number of Unsolicited Adverse Events in Healthy Participants Challenged With Wild Type SARS-CoV-2 — 45 Unsolicited Adverse Events
Phase 2 N=171 GLS-5310 Vaccine for the Prevention of SARS-CoV-2 (COVID-19)
SARS-CoV-2
Primary: Number of Serious Adverse Events — 0; 0; 0; 0 serious adverse events
Phase 1 N=24 Exploratory Ph I Trial of the Active IMP in Healthy Volunteers in Relation to COVID-19
Covid19
Primary: Pharmacokinetic Concentrations - (Maximum Plasma Concentration [Cmax]) — 57.2; 41.7; 46.5; 22.3 ng/mL — p=0.803
Phase 2 N=102 KBP-201 COVID-19 Vaccine Trial in Healthy Volunteers
Covid19
Primary: Solicited Administration Site Reactions — 19; 15; 20 participants
Phase 2 N=48 Influenza A 2009 H1N1 Challenge Study in Healthy Adults
Influenza
Primary: Percent MMID — 0; 0; 20; 47 percentage of participants
Phase 1 N=4 Challenge Infection of Healthy Adult Volunteers With RSV A2
Upper Respiratory Tract Infections
Primary: Participants With Detectable RSV Shedding in Nasopharyngeal Wash — 2; 4 Participants
Phase 1 N=50 Open-label Safety and Tolerability Study of CoVaccine HT™ in Healthy Volunteers
Vaccine
Primary: Safety Events — 20; 0; 40; 50 percentage of patients
Phase 1 N=12 A Study to Learn About the Study Medicine Called Nirmatrelvir/Ritonavir in People Who Are Healthy Volunteers Co-administered the Medicine Rosuvastatin
Pharmacokinetics · Healthy Volunteers
Primary: Area Under the Concentration-Time Curve From Time Zero (0) Extrapolated to Infinity (AUCinf) of Rosuvastatin in Period 1 and 2 — 58.62; 72.78 Nanogram*hour per milliliter
Phase 2 N=74 Evaluation of Anti-Hemagglutinin (Anti-HA) Antibodies as Protection From the Flu in Healthy People
Influenza
Primary: Number of Patients With Mild to Moderate Influenza Disease (MMID) — 6; 29 participants
Phase 1 N=38 Safety, Tolerability, and Pharmacokinetics of SAB-301 in Healthy Adults
Middle East Respiratory Syndrome Coronavirus
Primary: Number of Participants Having Adverse Events — 1; 2; 2; 4 Participants
Phase 2 N=91 Efficacy and Safety of CR6261 in an H1N1 Influenza Healthy Volunteer Human Challenge Model
H1N1 Influenza Healthy Volunteers
Primary: Area Under the Curve (AUC) of Viral Shedding — 48.56; 25.53 ViralLoad(log(copies/ml))per time(hours) — p=0.31
Phase 3 N=195 Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals
SARS-CoV-2 Infection · COVID-19
Primary: Percentage of Participants With Local Reactions Within 7 Days After Dose 1: Phase 1 — 0; 0; 8.3; 0 Percentage of participants
Phase 3 N=1,453 A Study to Learn About New COVID-19 RNA Vaccine Candidates in COVID-19 Vaccine-Experienced Healthy Individuals
SARS-CoV-2 Infection · COVID-19
Primary: Cohort 1: Percentage of Participants Reporting Local Reactions Within 7 Days After Study Vaccination — 5.8; 5.9; 3.8; 3.9 Percentage of participants
Phase 2 N=200 A Study of TAK-019 in Healthy Japanese Adults (COVID-19)
Prevention of Infection Disease Caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2)
Primary: Percentage of Participants With Solicited Local Adverse Events (AEs) for Six Subsequent Days Following First Vaccination — 4.0; 29.3; 4.0; 43.3 percentage of participants
Phase 1 N=28 A COVID-19 Study to Evaluate Safety and Pharmacokinetics of COVID-HIGIV Administered in Healthy Adults
COVID-19
Primary: Subjects With Adverse Events (AEs) up to 3 Days Post-dosing — 3; 4; 6; 2 Participants
Phase 2 N=153 Dose Finding Study to Evaluate The Safety, Tolerability and Immunogenicity of an Inactiviated, Adjuvanted SARS-CoV-2 Virus Vaccine Candidate Against Covid-19 in Healthy Subjects
SARS-CoV-2 Virus Infection
Primary: Frequency of Solicited AEs (Local and Systemic Reactions) Within 7 Days After Any Vaccination of the Primary Vaccination Series — 35; 31; 36; 32 events
N/A N=33 Dose, Safety, and Pathogenicity of a New Influenza A H3N2 Challenge Strain
Influenza A H3N2
Primary: Occurrence of Adverse Events Related to the Viral Challenge — 0; 0; 1; 6 Occurrence of adverse events
Phase 3 N=1,049 A Study to Learn About New COVD-19 RNA Vaccine Candidates for New Variants in Healthy Individuals
SARS-CoV-2 Infection · COVID-19
Primary: Percentage of Participants With Local Reactions Within 7 Days After Vaccination: SSA — 10.0; 4.0; 5.8; 5.4 Percentage of participants
Phase 1 N=120 Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis of SARS-CoV-2 Infection (COVID-19)
COVID-19 · COVID-19 Immunisation
Primary: Frequency of Any Medically-attended Adverse Events (MAAEs) — 7; 6; 5; 7 Participants
Phase 1 N=76 H1N1v Virus Challenge Study in Healthy Subjects
Influenza
Primary: Percentage of Healthy Participants Reporting Mild-to-Moderate Influenza Disease (MMID) by Baseline A/Bethesda/MM2/H1N1 Hemagglutination Inhibition (HAI) Antibody…
N/A N=58 The Development of a Human Model of Respiratory Syncytial Virus Infection
Respiratory Syncytial Virus Infections · Respiratory Viral Infections
Primary: Host Response to RSV Challenge Measured as Change From Baseline of Chemical Mediators in Nasal Fluid — 23 Participants
Phase 1 N=35 A Study to Determine the Tolerability of Intranasal LMN-301
COVID-19
Primary: Number of Participants With Adverse Events — 5; 9; 10; 8 Participants
Phase 2 N=200 A Study of TAK-919 in Healthy Japanese Adults (COVID-19)
Coronavirus Disease (COVID-19)
Primary: Percentage of Participants With Solicited Local Adverse Events (AEs) for Six Subsequent Days Following First Vaccination — 6.0; 82.7; 0.0; 2.0 percentage of participants
Early Phase 1 N=36 Immunogenicity of COVID-19 Vaccine Co-administration With Influenza Vaccine in Healthy Volunteers
COVID - 19
Primary: Geometric Mean (GM) of Interferon-gamma (IFN-γ) Response Against the SARS-CoV-2 Virus at Baseline — 19.6; 14; 12.6 SFCs/10⁶ PBMCs
Phase 1 N=60 Influenza Challenge Study to Determine the Optimal Infection Dose and Safety of a Recombinant H3N2 (A/Texas/71/2017 (H3N2, Clade 3C3a) Influenza Strain
Influenza
Primary: Number and Percentage of Participants With Symptomatic Influenza Virus Infection After Challenge. — 4; 5; 28; 0 Participants
N/A N=308 COVID-19 Vaccination and Outcomes in Individuals With and Without Immune Deficiencies and Dysregulations
Immunodeficiencies · Immune Dysregulations
Primary: Change in S and Receptor Binding Domain (RBD) Immunoglobulin G (IgG) Antibody Titer From Baseline Depending on Vaccine Manufacturer and Platform — 0.447333; 2.10678…
Phase 4 N=1,188 The Efficacy of the 2023-2024 Updated COVID-19 Vaccines Against COVID-19 Infection
COVID-19 · Vaccine-Preventable Diseases · SARS CoV 2 Infection
Primary: Number of Symptomatic SARS-CoV-2 Infections Between Randomized, Study-vaccinated Participants and the Comparator Group — 48; 94 Participants